PATENT CLAIM ANALYSIS

Application Number: 15918574
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["514", "289000"]

Abstract:
During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified in better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week.

Claim (Index 14):
A method of studying the binding activity of dextromethorphan in a human or non-human animal, said method comprising:\n administering a fluorinated analog of dextromethorphan to said human or non-human animal, and visualizing the fluorinated analog of dextromethorphan using a CAT scan in vivo imaging system.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.47059
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10482629', '12097157', '14100597', '11035213', '13415067']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7391458755565808
- 35 USC 102 Novelty (BERT): 0.5067292424056944
- Combined Prediction Score: 0.7159042122414923
- Mean Citation Score: 219.970642
- Max Citation Score: 239.18114
- Similarity Product: 150.0574953465986

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test